BIRC6
BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
Overview
Anti-apoptotic protein known as inhibitor of apoptosis (IAP) which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Unlike most IAPs, does not contain a RING domain and it is not a RING-type E3 ligase. Instead acts as a dual E2/E3 enzyme that combines ubiquitin conjugating (E2) and ubiquitin ligase (E3) activities in a single polypeptide.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.83, genetic association 0.19, somatic mutation 0.55). IntOGen calls it a driver in 21 cohorts (6 activating, 14 loss-of-function), covering Anal Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
- 1 · What it is
BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
Anti-apoptotic protein known as inhibitor of apoptosis (IAP) which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase.
- 3 · How drugs use it
No product in this corpus aims at BIRC6 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:13516 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NR09 (protein name, function text, keywords and locations (REST API)); CIViC gene BIRC6 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000115760 (association with cancer (MONDO_0004992) 0.63; (GraphQL API, CC0)); IntOGen BIRC6 (driver in 21 cohorts (Act 6, LoF 14); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Anti-apoptotic protein known as inhibitor of apoptosis (IAP) which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Unlike most IAPs, does not contain a RING domain and it is not a RING-type E3 ligase. Instead acts as a dual E2/E3 enzyme that combines ubiquitin conjugating (E2) and ubiquitin ligase (E3) activities in a single polypeptide. Ubiquitination is mediated by a non-canonical E1 ubiquitin activating enzyme UBA6. Ubiquitinates CASP3, CASP7 and CASP9 and inhibits their caspase activity; also ubiquitinates their procaspases but to a weaker extent. Ubiquitinates pro-apoptotic factors DIABLO/SMAC and HTRA2. Location: Golgi apparatus, trans-Golgi network membrane; Endosome; Cytoplasm, cytoskeleton, spindle pole; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome (UniProt). Locus 2p22.3 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 3 cohorts (BLCA)
- Breast cancer: IntOGen driver in 2 cohorts (BRCA)
- Renal cell carcinoma: IntOGen driver in 2 cohorts (CCRCC)
- Endometrial cancer: IntOGen driver in 2 cohorts (UCEC)
- Anal cancer: IntOGen driver in 1 cohort (ANSC)
- Colorectal cancer: IntOGen driver in 1 cohort (COADREAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 6 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 14 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"BIRC6" OR ABSTRACT:"BIRC6" OR TITLE:"baculoviral IAP repeat containing 6" OR ABSTRACT:"baculoviral IAP repeat containing 6" OR TITLE:"Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6" OR ABSTRACT:"Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6" OR TITLE:"BRUCE" OR ABSTRACT:"BRUCE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BIRC6, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPTPRC
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, Breast cancer (all types), IntOGen.
- TargetAPC
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, CIViC, IntOGen.
- TargetCOL1A1
Shares Anal cancer (squamous cell carcinoma), IntOGen, Open Targets Platform.
- JournalClinical colorectal cancer
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, Colorectal cancer.
- TargetSTK11
Shares Anal cancer (squamous cell carcinoma), Breast cancer (all types), CIViC, IntOGen.
- JournalJournal of gastrointestinal cancer
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, Colorectal cancer.
- TermRadiation dermatitis (skin reaction)
Shares Anal cancer (squamous cell carcinoma), Head and neck squamous cell carcinoma.
- CompanyOncolytics Biotech
Shares Anal cancer (squamous cell carcinoma), Colorectal cancer.